Asterisk invited me to participate in their “Weird” themed issue, so I wrote five thousand words on evil Atlantean cave dwarves. As always, I thought of the perfect framing just after I’d sent it out. The perfect framing is - where did Scientology come from? How did a 1940s sci-fi writer found a religion? Part of the answer is that 1940s sci-fi fandom was a really fertile place, where all of these novel mythemes about aliens, psychics, and lost civilizations were hitting a naive population certain that there must be something beyond the world they knew. This made them easy prey not just for grifters like Hubbard, but also for random schizophrenics who could write about their hallucinations convincingly. …but I didn’t think of that framing in time, so instead you get several sections of why it’s evil cave dwarves in particular, and why that theme seems to recur throughout all lands and ages: https://www.astralcodexten.com/p/deros-and-the-ur-abduction-in-asterisk https://asteriskmag.com/issues/09/deros-and-the-ur-abduction
--------
34:39
More Drowning Children
People love trying to find holes in the drowning child thought experiment. This is natural: it’s obvious you should save the child in the scenario, but much less obvious that you should give lots of charity to poor people (as it seems to imply). So there must be some distinction between the two scenarios. But most people’s cursory and uninspired attempts to find these fail. https://www.astralcodexten.com/p/more-drowning-children
--------
21:22
Misophonia: Beyond Sensory Sensitivity
Jake Eaton has a great article on misophonia in Asterisk. Misophonia is a condition in which people can’t tolerate certain noises (classically chewing). Nobody loves chewing noises, but misophoniacs go above and beyond, sometimes ending relationships, shutting themselves indoors, or even deliberately trying to deafen themselves in an attempt to escape. So it’s a sensory hypersensitivity, right? Maybe not. There’s increasing evidence - which I learned about from Jake, but which didn’t make it into the article - that misophonia is less about sound than it seems. Misophoniacs who go deaf report that it doesn’t go away. Now they get triggered if they see someone chewing. It’s the same with other noises. Someone who gets triggered by the sound of forks scraping against a table will eventually get triggered by the sight of the scraping fork. Someone triggered by music will eventually get triggered by someone playing a music video on mute. Maybe this isn’t surprising? https://www.astralcodexten.com/p/misophonia-beyond-sensory-sensitivity
--------
12:03
OpenAI Nonprofit Buyout: Much More Than You Wanted To Know
Last month, I put out a request for experts to help me understand the details of OpenAI’s forprofit buyout. The following comes from someone who has looked into the situation in depth but is not an insider. Mistakes are mine alone. Why Was OpenAI A Nonprofit In The First Place? In the early 2010s, the AI companies hadn’t yet discovered scaling laws, and so underestimated the amount of compute (and therefore money) it would take to build AI. DeepMind was the first victim; originally founded on high ideals of prioritizing safety and responsible stewardship of the Singularity, it hit a financial barrier and sold to Google. This scared Elon Musk, who didn’t trust Google (or any corporate sponsor) with AGI. He teamed up with Sam Altman and others, and OpenAI was born. To avoid duplicating DeepMind’s failure, they founded it as a nonprofit with a mission to “build safe and beneficial artificial general intelligence for the benefit of humanity”. But like DeepMind, OpenAI needed money. At first, they scraped by with personal donations from Musk and other idealists, but as the full impact of scaling laws became clearer, Altman wanted to form a forprofit arm and seek investment. Musk and Altman disagree on what happened next: Musk said he objected to the profit focus, Altman says Musk agreed but wanted to be in charge. In any case, Musk left, Altman took full control, and OpenAI founded a forprofit subsidiary. This subsidary was supposedly a “capped forprofit”, meaning that their investors were capped at 100x return - if someone invested $1 million, they could get a max of $100 million back, no matter how big OpenAI became - this ensured that the majority of gains from a Singularity would go to humanity rather than investors. But a capped forprofit isn’t a real kind of corporate structure; in real life OpenAI handles this through Profit Participation Units, a sort of weird stock/bond hybrid which does what OpenAI claims the capped forprofit model is doing. https://www.astralcodexten.com/p/openai-nonprofit-buyout-much-more
--------
25:13
The Ozempocalypse Is Nigh
Sorry, you can only get drugs when there's a drug shortage. Three GLP-1 drugs are approved for weight loss in the United States: Semaglutide (Ozempic®, Wegovy®, Rybelsus®) Tirzepatide (Mounjaro®, Zepbound®) Liraglutide (Victoza®, Saxenda®) …but liraglutide is noticeably worse than the others, and most people prefer either semaglutide or tirzepatide. These cost about $1000/month and are rarely covered by insurance, putting them out of reach for most Americans. …if you buy them from the pharma companies, like a chump. For the past three years, there’s been a shortage of these drugs. FDA regulations say that during a shortage, it’s semi-legal for compounding pharmacies to provide medications without getting the patent-holders’ permission. In practice, that means they get cheap peptides from China, do some minimal safety testing in house, and sell them online. So for the past three years, telehealth startups working with compounding pharmacies have sold these drugs for about $200/month. Over two million Americans have made use of this loophole to get weight loss drugs for cheap. But there was always a looming question - what happens when the shortage ends? Many people have to stay on GLP-1 drugs permanently, or else they risk regaining their lost weight. But many can’t afford $1000/month. What happens to them? Now we’ll find out. At the end of last year, the FDA declared the shortage over. The compounding pharmacies appealed the decision, but last month the FDA confirmed its decision was final. As of March 19 (for tirzepatide) and April 22 (for semaglutide), compounding pharmacies will no longer be able to sell cheap GLP-1 drugs. Let’s take a second to think of the real victims here: telehealth company stockholders. https://www.astralcodexten.com/p/the-ozempocalypse-is-nigh
USA